clinical trial · NCT04138277
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
Pompe Disease (Late-onset)AT2221ATB200
brief summary
This is a multicenter, international open-label extension study of ATB200/AT2221 in adult subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
started
Dec 18, 2019
primary completion
Dec 31, 2024
completion
Dec 31, 2024
last updated
Mar 5, 2026
detailed description
This is an open-label extension study for subjects who completed the ATB200-03 study. The subjects will stay in this study until regulatory approval or marketing authorization and/or commercialization in the participating subject's country.
official title
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease (LOPD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol